JP6411998B2 - 抗トランスグルタミナーゼ２抗体 - Google Patents

抗トランスグルタミナーゼ２抗体 Download PDF

Info

Publication number
JP6411998B2
JP6411998B2 JP2015513275A JP2015513275A JP6411998B2 JP 6411998 B2 JP6411998 B2 JP 6411998B2 JP 2015513275 A JP2015513275 A JP 2015513275A JP 2015513275 A JP2015513275 A JP 2015513275A JP 6411998 B2 JP6411998 B2 JP 6411998B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
chain variable
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015513275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519897A5 (cg-RX-API-DMAC7.html
JP2015519897A (ja
Inventor
ジョンソン、ティム
ワトソン、フィル
マシューズ、デイヴィッド
ブラウン、アレックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
Medical Research Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46546551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6411998(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Research Council Technology filed Critical Medical Research Council Technology
Publication of JP2015519897A publication Critical patent/JP2015519897A/ja
Publication of JP2015519897A5 publication Critical patent/JP2015519897A5/ja
Application granted granted Critical
Publication of JP6411998B2 publication Critical patent/JP6411998B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
JP2015513275A 2012-05-24 2013-05-24 抗トランスグルタミナーゼ２抗体 Active JP6411998B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1209096.5A GB201209096D0 (en) 2012-05-24 2012-05-24 Compounds
GB1209096.5 2012-05-24
PCT/GB2013/051373 WO2013175229A1 (en) 2012-05-24 2013-05-24 Anti -transglutaminase 2 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018104139A Division JP2018166510A (ja) 2012-05-24 2018-05-30 抗トランスグルタミナーゼ２抗体

Publications (3)

Publication Number Publication Date
JP2015519897A JP2015519897A (ja) 2015-07-16
JP2015519897A5 JP2015519897A5 (cg-RX-API-DMAC7.html) 2016-06-30
JP6411998B2 true JP6411998B2 (ja) 2018-10-24

Family

ID=46546551

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015513275A Active JP6411998B2 (ja) 2012-05-24 2013-05-24 抗トランスグルタミナーゼ２抗体
JP2018104139A Pending JP2018166510A (ja) 2012-05-24 2018-05-30 抗トランスグルタミナーゼ２抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018104139A Pending JP2018166510A (ja) 2012-05-24 2018-05-30 抗トランスグルタミナーゼ２抗体

Country Status (39)

Country Link
US (3) US10005846B2 (cg-RX-API-DMAC7.html)
EP (2) EP2855530B1 (cg-RX-API-DMAC7.html)
JP (2) JP6411998B2 (cg-RX-API-DMAC7.html)
KR (1) KR102091223B1 (cg-RX-API-DMAC7.html)
CN (1) CN104321346B (cg-RX-API-DMAC7.html)
AU (1) AU2013265025B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029089B1 (cg-RX-API-DMAC7.html)
CA (1) CA2874488C (cg-RX-API-DMAC7.html)
CL (1) CL2014003125A1 (cg-RX-API-DMAC7.html)
CO (1) CO7151528A2 (cg-RX-API-DMAC7.html)
CY (2) CY1121932T1 (cg-RX-API-DMAC7.html)
DK (2) DK3521315T3 (cg-RX-API-DMAC7.html)
EA (1) EA036810B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14030942A (cg-RX-API-DMAC7.html)
ES (2) ES2835383T3 (cg-RX-API-DMAC7.html)
GB (1) GB201209096D0 (cg-RX-API-DMAC7.html)
HR (2) HRP20191293T1 (cg-RX-API-DMAC7.html)
HU (2) HUE052490T2 (cg-RX-API-DMAC7.html)
IL (1) IL235369B (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02231A (cg-RX-API-DMAC7.html)
LT (2) LT3521315T (cg-RX-API-DMAC7.html)
MA (1) MA37670B1 (cg-RX-API-DMAC7.html)
ME (1) ME03393B (cg-RX-API-DMAC7.html)
MX (1) MX367517B (cg-RX-API-DMAC7.html)
MY (1) MY185966A (cg-RX-API-DMAC7.html)
NZ (1) NZ701424A (cg-RX-API-DMAC7.html)
PE (1) PE20150346A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502582A1 (cg-RX-API-DMAC7.html)
PL (2) PL3521315T3 (cg-RX-API-DMAC7.html)
PT (2) PT3521315T (cg-RX-API-DMAC7.html)
RS (2) RS61286B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201407053YA (cg-RX-API-DMAC7.html)
SI (2) SI2855530T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100014T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000458A1 (cg-RX-API-DMAC7.html)
TR (1) TR201906781T4 (cg-RX-API-DMAC7.html)
UA (1) UA117657C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013175229A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408213B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法
FR3117599B1 (fr) * 2020-12-16 2024-11-29 Oreal Méthode de pronostic et/ou de diagnostic d’un état pelliculaire du cuir chevelu
GB202115121D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115127D0 (en) 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
CN118354792A (zh) 2021-11-18 2024-07-16 Ucb生物制药有限责任公司 用于治疗进行性慢性间质性肺部疾病的方法
GB202116665D0 (en) 2021-11-18 2022-01-05 UCB Biopharma SRL Method for the treatment of a scleroderma disease
GB202118010D0 (en) 2021-12-13 2022-01-26 UCB Biopharma SRL Method for detecting and/or quantifying crosslinks formed by transglutaminases
CN116515786B (zh) * 2023-04-26 2024-05-28 广东医科大学 一种人tgm3乙酰化多肽、抗原、抗体及其制备方法和应用
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
WO1992012238A1 (en) 1991-01-04 1992-07-23 The Board Of Regents, University Of Texas System Cloning and expression of tissue transglutaminases
AU6620596A (en) 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
CA2514942A1 (en) 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Methods and compositions for the treatment of parkinson's disease and other a-synucleinopathies
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
WO2008063760A2 (en) 2006-10-18 2008-05-29 The University Of Texas M.D. Anderson Cancer Center Methods for treating cancer targeting transglutaminase
CA2721716C (en) * 2008-04-24 2019-09-24 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
CN102405056A (zh) 2009-03-19 2012-04-04 昆士兰技术大学 用于生长因子信号转导的靶标和治疗方法
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
HU0900195D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
EP2579861A2 (en) 2010-06-02 2013-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Transglutaminase 2 inhibitors for use in the prevention or treatment of rapidly progressive glomerulonephritis
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase

Also Published As

Publication number Publication date
PL3521315T3 (pl) 2021-08-23
IL235369B (en) 2019-05-30
CA2874488A1 (en) 2013-11-28
GB201209096D0 (en) 2012-07-04
CY1123926T1 (el) 2022-05-27
CO7151528A2 (es) 2014-12-29
JP2018166510A (ja) 2018-11-01
US10961319B2 (en) 2021-03-30
RS59135B1 (sr) 2019-09-30
US10005846B2 (en) 2018-06-26
CN104321346B (zh) 2018-12-07
CL2014003125A1 (es) 2015-08-21
ES2728856T3 (es) 2019-10-29
SMT202100014T1 (it) 2021-03-15
SI2855530T1 (sl) 2019-08-30
HUE052490T2 (hu) 2021-04-28
ECSP14030942A (es) 2015-09-30
TN2014000458A1 (en) 2016-03-30
MY185966A (en) 2021-06-14
EP3521315B1 (en) 2020-10-14
BR112014029089B1 (pt) 2023-04-25
HRP20202059T1 (hr) 2021-02-19
SG11201407053YA (en) 2014-12-30
CY1121932T1 (el) 2020-10-14
HUE045539T2 (hu) 2019-12-30
KR102091223B1 (ko) 2020-03-20
MX367517B (es) 2019-08-26
RS61286B1 (sr) 2021-02-26
US20210101999A1 (en) 2021-04-08
HRP20191293T1 (hr) 2019-10-18
PL2855530T3 (pl) 2019-10-31
MA37670B1 (fr) 2019-12-31
IL235369A0 (en) 2014-12-31
EP2855530B1 (en) 2019-05-01
PT3521315T (pt) 2020-10-29
PE20150346A1 (es) 2015-03-05
PH12014502582B1 (en) 2015-01-21
US20180355060A1 (en) 2018-12-13
SI3521315T1 (sl) 2020-12-31
MA37670A1 (fr) 2016-05-31
US20150218289A1 (en) 2015-08-06
DK3521315T3 (da) 2020-11-09
BR112014029089A2 (pt) 2019-06-25
AU2013265025B2 (en) 2018-04-26
SMT201900407T1 (it) 2019-09-09
LT2855530T (lt) 2019-07-25
EA201492162A1 (ru) 2015-03-31
EP2855530A1 (en) 2015-04-08
HK1203974A1 (en) 2015-11-06
CA2874488C (en) 2021-09-07
ZA201408213B (en) 2020-02-26
PT2855530T (pt) 2019-07-08
AU2013265025A1 (en) 2014-12-04
UA117657C2 (uk) 2018-09-10
JP2015519897A (ja) 2015-07-16
CN104321346A (zh) 2015-01-28
IN2014MN02231A (cg-RX-API-DMAC7.html) 2015-07-24
EA036810B1 (ru) 2020-12-23
LT3521315T (lt) 2020-12-28
ES2835383T3 (es) 2021-06-22
TR201906781T4 (tr) 2019-05-21
MX2014014264A (es) 2015-05-15
ME03393B (me) 2020-01-20
WO2013175229A1 (en) 2013-11-28
KR20150013340A (ko) 2015-02-04
US11718686B2 (en) 2023-08-08
PH12014502582A1 (en) 2015-01-21
NZ701424A (en) 2016-08-26
DK2855530T3 (da) 2019-06-24
EP3521315A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
JP6411998B2 (ja) 抗トランスグルタミナーゼ２抗体
JP7592022B2 (ja) 抗クローディン１８．２抗体及びその用途
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
JP2017534661A (ja) がんの治療における使用のための抗−ｃｋ８抗体
CN111825766B (zh) 抗il-4r单域抗体及其应用
KR101854529B1 (ko) 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
CN110964107B (zh) Met结合分子、其组合和用途
CN112770786B (zh) 利用抗体的癌症治疗
RU2846776C1 (ru) Антитело против нектина-4, конъюгат, включающий его, и их применение
HK40012662A (en) Anti-transglutaminase 2 antibodies
HK40012662B (en) Anti-transglutaminase 2 antibodies
HK1203974B (en) Anti -transglutaminase 2 antibodies
KR20250123919A (ko) 항-tgf베타 수용체 1 항체 및 그의 용도
CN120322460A (zh) 单价cd47结合蛋白
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150120

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180530

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180927

R150 Certificate of patent or registration of utility model

Ref document number: 6411998

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250